A pooled analysis of over 18,000 participants supports the benefits of finerenone across cardio-kidney-metabolic conditions
en-GBde-DEes-ESfr-FR

A pooled analysis of over 18,000 participants supports the benefits of finerenone across cardio-kidney-metabolic conditions


London, United Kingdom – 1 September 2024: A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and kidney outcomes were observed, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.1

Dr. Muthiah Vaduganathan of the Brigham and Women's Hospital and Harvard Medical School, Boston, USA, explained why the meta-analysis was conducted: “It is increasingly being recognised that cardiovascular diseases, chronic kidney disease (CKD) and metabolic conditions, such as diabetes, co-exist in the same patients and share common disease pathways. The non-steroidal mineralocorticoid receptor antagonist, finerenone, has been shown to reduce the risk of cardiovascular events and kidney failure in two trials in patients with CKD with type 2 diabetes2,3 and has recently been shown to reduce worsening heart failure (HF) events in a trial in patients with HF with mildly reduced or preserved ejection fraction.4 We combined data from these three large trials, and although we did not observe a significant reduction in cardiovascular death, all-cause mortality was significantly reduced and there were clinically relevant improvements in other outcomes.”

The participant-level pooled FINE-HEART analysis was conducted with data from the FIDELIO-DKD2 and FIGARO-DKD3 trials in patients with CKD and type 2 diabetes and the FINEARTS-HF4 trial in patients with heart failure (HF) and mildly reduced or preserved ejection fraction. The prespecified primary outcome was time to cardiovascular death. The definition of cardiovascular death differed slightly between the three trials and was harmonised for FINE-HEART as time to cardiovascular death (excluding undetermined deaths). Other prespecified outcomes included a kidney composite outcome (defined as a sustained decrease in estimated glomerular filtration rate [eGFR] to ≥50% from baseline, sustained decline in eGFR to <15 mL/min/1.73 m2, kidney failure and death due to kidney causes), HF hospitalisation, composite of cardiovascular death or HF hospitalisation, and all-cause death.

The analysis included data from 18,991 participants. The mean age was 67 years and 35% were women. At baseline, 81% had diabetes, 84% had CKD and 37% had HF, with 12% having all three conditions.

Over 2.9 years median follow-up, cardiovascular death occurred in 4.4% of patients in the finerenone group and 5.0% of patients in the placebo group (hazard ratio [HR] 0.89; 95% confidence interval [CI] 0.78–1.01; p=0.076). Death from any cause occurred in 11.0% of participants in the finerenone group and 12.0% in the placebo group (HR 0.91; 95% CI 0.84–0.99; p=0.027). Finerenone further reduced the risk of HF hospitalisation (HR 0.83; 95% CI 0.75–0.92; p<0.001) and the composite kidney outcome (HR 0.80; 95% CI 0.72–0.90; p<0.001).

The incidence of any serious adverse event was lower with finerenone than placebo (34.6% vs. 36.6%), although serious adverse events leading to drug discontinuation were higher with finerenone (5.4% vs. 4.6%). Laboratory-defined hyperkalaemia was higher with finerenone, while laboratory-defined hypokalaemia was lower.

Dr. Vaduganathan concluded: “This large, pooled analysis failed to demonstrate a significant reduction in cardiovascular death, but this may be due to the definition of cardiovascular death used and the classification of deaths of undetermined causes. We did find important reductions in all-cause death and a broad range of other cardio-kidney outcomes including kidney disease progression and HF hospitalisations. Pooling these data summarises complementary lines of evidence which support a disease-modifying potential role of finerenone across the cardio-kidney-metabolic spectrum.”

ENDS

References and notes

1‘FINE-HEART - Participant-level pooled analysis of finerenone in heart failure and chronic kidney disease trials’ will be discussed during Hot Line 7 on Sunday 1 September in room London.

2Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–2229.

3Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–2263.

4‘FINEARTS-HF - Finerenone in heart failure with mildly reduced and preserved ejection fraction’ will be discussed during Hot Line 7 on Sunday 1 September in room London.
Regions: Europe, France, North America, United States
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2024 by AlphaGalileo Terms Of Use Privacy Statement